12:00 AM
Jul 03, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Multikine: Began Phase II trial

Cel-Sci Corp. (CVM; Berlin:LSR), Vienna, Va.
Product: Multikine
Business: Cancer
Therapeutic category: Immune stimulation
Target: Immune cells

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >